Randomized, Crossover Bioequivalence Study of PL-ASA Versus Immediate Release Aspirin in Healthy Volunteers.

A Randomized, Actively-Controlled, Crossover Bioequivalence Study of a Novel Pharmaceutical Lipid-Aspirin Complex Formulation at 325 mg Dose Versus Immediate Release Aspirin in Healthy Volunteers

This trial is a randomized, actively-controlled, open-label, 2-way crossover bioequivalence study to determine PK parameters following treatment with test aspirin product (PL-ASA capsules) and reference aspirin product (IR-ASA tablets) administered at a single dose of 325 mg.

Study Overview

• Status: Completed
• Conditions: Bioequivalence
• Intervention / Treatment: Drug: Pharmaceutical-lipid aspirin (PL-ASA)

Detailed Description

Healthy volunteers will be asked to sign informed consent prior to conduct any protocol specified activities at screening. A total of 20 eligible subjects will be randomized, in a fasted state, to 1 of 2 sequences of study drug administration (each study drug dose contains 325 mg aspirin) at 1:1 ratio:

• PL-ASA capsule, IR-ASA tablet
• IR-ASA tablet, PL-ASA capsule

After completion of the first treatment on Day 1 and following the 24 hours of sample collection, a minimum of a 7-day washout period will be required before all subjects are crossed over and receive treatment with the alternative compound; i.e., subject randomized to receive PL-ASA capsule as a first treatment will receive IR-ASA tablet as the second treatment, and vice-versa.

• Study Type: Interventional
• Enrollment (Actual): 24
• Phase: Phase 1

Contacts and Locations

Study Locations

• United States
  • Kansas
    • Lenexa, Kansas, United States, 66219
      • PRA-EDS

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Male or female subjects at least 18 years of age without known acute or chronic medical conditions requiring treatment;
• If female, a negative pregnancy test and not nursing;
• If female and of childbearing potential, use of adequate birth control for the duration of the study (i.e., barrier methods such as female diaphragm or male condom; intrauterine devices, hormonal implants, pill, patch, shot, vaginal ring, etc.; total abstinence from heterosexual intercourse when it is in line with the preferred and usual lifestyle of the subject; vasectomized partner);
• Non-smoker, including no use of any smoking cessation nicotine-containing products (i.e., nicotine replacement therapy [patch, spray, inhaler, gum, lozenge, bupropion SR, clonidine and nortriptyline], e-cigarettes, etc.) for at least 3 months prior to screening;
• Consumes on average no more than 2 alcoholic drinks (1 drink is defined as approximately 12 oz of regular beer, 5 oz of wine, or 1.5 oz of hard liquor) per day for at least 30 days prior to screening;
• A body mass index (BMI) between 18 to 32 kg/m2;
• Agrees to refrain from alcohol consumption for 48 hours prior to and 48 hours after drug administration; and
• Able and willing to provide written informed consent prior to the study.

Exclusion Criteria:

• Abnormal screening/baseline laboratory parameters deemed to be clinically significant by the Investigator;
• Positive urine alcohol and drug screen result;
• Use of any prescription medications other than hormone replacement therapy, thyroid replacement therapy, or oral contraceptive within 3 days prior to study drug administration;
• Use of antacid medications, including over-the-counter (OTC) products within 3 days prior to study drug administration;
• Use of dietary or herbal supplements containing salicylates, fish oil, or any vitamins within 2 weeks of study drug administration;

• Use of any of the following medications within 2 weeks prior to study drug administration:

  1. Non-steroidal anti-inflammatory drugs (NSAIDs), including aspirin or aspirin-containing products and acetaminophen.
  2. Any anti-platelet agent, including clopidogrel, prasugrel, ticagrelor, ticlopidine, cangrelor, dipyridamole, cilostazol, vorapaxar, abciximab, eptifibatide, tirofiban, or triflusal.
  3. Any anti-coagulant agent, including warfarin, acenocoumarol, phenprocoumon, phenindione, rivaroxaban, dabigatran, apixaban, edoxaban, heparin, enoxaparin, fondaparinux, ximelagatran, argatroban, lepirudin, hirudin, or bivalirudin.
• Use of an investigational agent within the past 30 days prior to drug administration.
• Hypersensitivity or contraindications to aspirin, ibuprofen, or other NSAID;
• Soy allergy or sensitivity;

• History of:

  1. Gastrointestinal problems including ulcers, frequent indigestion, or frequent heartburn.
  2. Coronary disease, stroke, or congestive heart failure.
  3. Asthma, nasal polyps, or angioedema other than resolved childhood asthma.
  4. Kidney or liver disease.
  5. Thrombocytopenia, neutropenia, bleeding disorder, or history of non-trauma related hemorrhage.
  6. Chronic hypertension.
• Current enrollment in another investigational trial; or
• History of cancer within the last 5 years (except for skin cancer resolved by excision, or cervical cancer adequately treated).

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Basic Science
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: Single

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Other: PL-ASA capsule, then IR-ASA tablet; One PL-ASA 325 mg capsule, 14 day washout then one IR-ASA 325 mg tablet	Drug: Pharmaceutical-lipid aspirin (PL-ASA); Subjects receive the first drug, followed by a 7-day washout period, then receive the second drug.; Other Names: Immediate-release aspirin (IR-ASA)
Other: IR-ASA tablet, then PL-ASA capsule; One IR-ASA 325 mg tablet, 14 day washout, then one PL-ASA 325 mg capsule,	Drug: Pharmaceutical-lipid aspirin (PL-ASA); Subjects receive the first drug, followed by a 7-day washout period, then receive the second drug.; Other Names: Immediate-release aspirin (IR-ASA)

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Bioequivalence of single-dose acetylsalicylic acid PK of the PL-ASA formulation to IR-ASA in healthy volunteers at 325 mg dose level.	Bioequivalence using serum determinations of acetylsalicylic acid concentration	24 hours after dosing

Collaborators and Investigators

• Sponsor: PLx Pharma

Study record dates

Study Major Dates

• Study Start (Actual): May 7, 2020
• Primary Completion (Actual): June 29, 2020
• Study Completion (Actual): October 1, 2020

Study Registration Dates

• First Submitted: September 16, 2021
• First Submitted That Met QC Criteria: September 16, 2021
• First Posted (Actual): September 24, 2021

Study Record Updates

• Last Update Posted (Actual): April 27, 2022
• Last Update Submitted That Met QC Criteria: April 20, 2022
• Last Verified: September 1, 2021

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Peripheral Nervous System Agents; Enzyme Inhibitors; Analgesics; Sensory System Agents; Anti-Inflammatory Agents, Non-Steroidal; Analgesics, Non-Narcotic; Anti-Inflammatory Agents; Antirheumatic Agents; Fibrinolytic Agents; Fibrin Modulating Agents; Platelet Aggregation Inhibitors; Cyclooxygenase Inhibitors; Antipyretics; Aspirin
• Other Study ID Numbers: PL-ASA-009

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No